Abstract
Bintrafusp alfa, an investigational, first-in-class bifunctional fusion protein composed of the extracellular domain of the TGF-βRII receptor (a TGF-β “trap”) fused to a human IgG1 mAb blocking PD-L1, has displayed clinical activity and manageable safety in patients with heavily pretreated solid tumors from two phase I studies (NCT02517398 and NCT02699515). Although bintrafusp alfa–associated adverse events (AEs) are mostly mild to moderate, effective management is essential to minimize disruptions in treatment and maintain quality of life (QOL).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.